The JAK inhibitor (JAKi) tofacitinib was associated with an increased risk of serious adverse events compared to TNF-inhibitors in the treatment of rheumatoid arthritis in the ORAL surveillance study (NCT02092467). In this interview, touchIMMUNOLOGY were delighted to speak with Dr. Kim Lauper (Geneva University Hospitals, Genéve, Switzerland) around her study assessing the safety of JAKis compared to other biologics in a real-world population.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Evaluation of Treatment Discontinuation Due to Adverse Events, and the Effect of Cardiovascular Risk Factors or Type of JAK-inhibitors: An International Collaboration of Registries of Rheumatoid Arthritis Patients.‘ (Abstract number: 0290) was presented at the ACR Convergence, November 10–14, 2022.
- What did the ORAL surveillance study teach us about the safety profile of tofacitinib, compared to TNF-inhibitors? (0:26)
- What were the aims and design of your study? (1:24)
- What were the rates of treatment discontinuation of JAK inhibitors compared with other biologic therapies? (3:08)
- What were your conclusions in terms of the future use of JAK inhibitors? (5:05)
Disclosures: Kim Lauper discloses receiving grant/ research support from Galapagos, Eli Lilly, AbbVie, and Pfizer; serving on advisory boards for Pfizer; and participating in speaker’s bureaus for Viatris, Gilead-Galapgos, and Pfizer.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ACR Convergence 2022.
Share this Video
Related Videos In Rheumatoid Arthritis
Kevin Winthrop, ACR 2022: Integrated safety analysis of filgotinib in moderately to severely active rheumatoid arthritis
Filgotinib, is an oral Janus kinase 1 inhibitor approved in Europe, Japan, and the UK for the treatment of patients with moderately to severely active rheumatoid arthritis (RA). In this touchIMMUNOLOGY interview, we caught up with Prof. Kevin Winthrop (Oregon Health & Science University, Portland, OR, USA) to discuss the objectives, methodology and findings from […]
Paul Studenic, ACR 2022: A validation study of the revised ACR/EULAR remission criteria for rheumatoid arthritis
ACR and EULAR endorsed provisional criteria, both Boolean and index-based, to define remission in rheumatoid arthritis over 10 years ago, in 2022 a revision of the remission criteria has been made. touchIMMUNOLOGY were delighted to speak with Dr. Paul Studenic (Medical University of Vienna, Vienna, Austria) to discuss the methodology and findings of the validation […]
Paul Studenic, ACR 2022: The 2022 revision of the ACR/EULAR remission criteria for rheumatoid arthritis
ACR and EULAR endorsed provisional criteria, both Boolean and index-based, to define remission in rheumatoid arthritis (RA) over 10 years ago, in 2022 a revision of the remission criteria has been made. touchIMMUNOLOGY were delighted to speak with Dr. Paul Studenic (Medical University of Vienna, Vienna, Austria) to discuss the limitations of the Boolean and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!